Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
| ▸ | PKM | P14618 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 3/20 | 0.41 |
| ▸ | AKT1 | P31749 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17486609 | 0.91 | MAPT (0.59) | MAPTPKMALDH1A1CHRM3AKT1 | |
| SCHEMBL17485213 | 0.91 | MAPT (0.59) | MAPTPKMALDH1A1CHRM3AKT1 | |
| SCHEMBL17485233 | 0.91 | MAPT (0.59) | MAPTPKMALDH1A1CHRM3AKT1 | |
| SCHEMBL12617850 | 0.87 | MAPT (0.74) | MAPTPKMTACR1 | |
| SCHEMBL12652627 | 0.87 | MAPT (0.74) | MAPTPKMTACR1 | |
| SCHEMBL3007095 | 0.85 | MAPT (0.97) | MAPTPKMALDH1A1CHRM3TACR1 | |
| SCHEMBL1105979 | 0.85 | MAPT (0.97) | MAPTPKMALDH1A1CHRM3TACR1 | |
| SCHEMBL1095808 | 0.85 | MAPT (0.97) | MAPTPKMALDH1A1CHRM3TACR1 | |
| SCHEMBL3209495 | 0.85 | MAPT (0.97) | MAPTPKMALDH1A1CHRM3TACR1 | |
| SCHEMBL28660767 | 0.85 | MAPT (0.97) | MAPTPKMALDH1A1CHRM3TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | CASR, CYP2R1, HCAR1 | MAPT 4561/4885PKM 3074/4885ALDH1A1 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.